Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc. Show more
Location: 5005 McConnell Avenue, Los Angeles, CA, 90066, United States | Website: https://www.armatapharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
108.7M
52 Wk Range
$0.90 - $3.00
Previous Close
$3.00
Open
$3.00
Volume
25,334
Day Range
$2.97 - $3.14
Enterprise Value
248.3M
Cash
4.328M
Avg Qtr Burn
-7.895M
Insider Ownership
69.48%
Institutional Own.
2.03%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AP-PA02 Details Non-Cystic Fibrosis Bronchiectasis | Phase 2 Update | |
AP-SA02 Details Bacterial infection | Phase 2a Update | |
AP-PA02 Details Cystic fibrosis | Phase 1/2 Update |